Albert David Limited is an India-based pharmaceutical company. The Company's principal business is manufacturing and trading of pharmaceutical formulations, infusion solutions, herbal dosage forms and bulk drugs by way of domestic sale or export. Its product categories include formulations and bulk drugs. Its product range includes Placentrex range, Anaflam range and BREAZE range. Its formulations include parenteral, oral/enteral, topical agents and vision care. Its parenteral categories include amino acids infusion, anti-microbial, anti-leishmaniasis (kalazar), haemostat (inj), lvp, neurotropic vitamin and placenta extract. The Company's oral/enteral categories include amino acids oral, anthelmintic, anti-microbial, anti-ulcer ants, anti-vertigo, appetite stimulants, anti-tubercular, expectorant / cough syrup, hematinic, haemostat, hepato protective (ayurveda) and hepato protective (others). Its vision care categories include anti glaucoma, anti-infective and NSAID.As of 25 May 2026, Albert David share price is ₹721.00. The stock opened at ₹705.80, compared to its previous close of ₹705.80. During today's trading session, Albert David share price moved in the range of ₹705.80 to ₹727.95, with an average price of ₹716.88 for the day. Looking at its last 52-week, the stock has touched a low of ₹705.80 and a high of ₹727.95. On the performance front, Albert David share price has declined by 10.32% over the last six months and is down 13.19% on a year-on-year basis.
The market capitalization of Albert David is ₹401 Crs, with a P/E ratio of -268.3 and a dividend yield of 0.71%.